Here are four things to know about the company’s stock:
• Barclays currently has an overweight rating on the stock.
• K2M has a one-year low of $12.31 and a one-year high of $23.63.
• The stock’s 50-day moving average is $19 and its 200-day moving average is $17.
• The company’s market cap is $859.92 million.
More articles on devices:
Amedica to present CASCADE clinical results
Dr. Jacob Rosenstein performs 1st spinal fusion with Arena-C HA — 5 thing to know
1st reverse shoulder replacement using Zimmer device successfully completed in U.S.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
